Stem-Cell Transplant Consolidation for Aggressive Non-Hodgkin Lymphoma

No overall survival advantage was identified for higher-risk patients in first remission.

Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and high-intermediate or high risk International Prognostic Index (IPI) scores have poorer outcomes with standard immuno-chemotherapy induction than do those with lower-risk disease. To assess the efficacy of consolidation therapy with autologous stem cell transplantation (ASCT) during first remission, investigators conducted a phase III, multicenter trial involving patients aged 15 to 65 with IPI scores of 3 to 5. In addition to DLBCL patients, those with T-cell large cell lymphoma, follicular grade 3 lymphoma, and Burkitt or Burkitt-like lymphoma were also enrolled.

Patients received 5 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Stem-Cell Transplant Consolidation for Aggressive Non-Hodgkin Lymphoma

Topics

Reviewing Author